Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Automationguyon Feb 28, 2012 8:51pm

341 Views

Post# 19601786

RE: Canaguaro ..Quetzal is producing revenue

From the new powerpoint ...

q? Existing production and exploration upside potential provide balanced portfolio of risk

q? Current net production of approximately 200 boe/d from Canaguaro

and my post from the website of the ANH was :PRODUCCIÓN DE CRUDO POR CAMPO - BPDC

Canaguaro

2011*=204

A good news : No short sell as February 15th for Brownstone and Quetzal....if the news was supposed to be bad we would have seen shorts and do remind that Brownstone insiders have invested a lot in the last 4 months . Let's hope that

Mani-1 will be the one !!

q?

Bullboard Posts

Gold vs. bitcoin, where should you invest?